Ocular Therapeutix is advancing its innovative tyrosine kinase inhibitor implant, OTX-TKI, into phase 3 clinical trials for diabetic retinopathy following encouraging results from early-stage studies. The announcement came during the Retina 2025 conference in Koloa, Hawaii, where researchers presented promising efficacy data from the phase 1 HELIOS trial.
The axitinib intravitreal implant, designed to block VEGF receptors 1, 2, and 3, demonstrated significant therapeutic potential in treating diabetic retinopathy. According to Dr. Peter K. Kaiser of Ocular Therapeutix, patients receiving the implant showed either stability or improvement in their diabetic retinopathy condition throughout the one-year follow-up period.
Dual Therapeutic Benefits Observed
Beyond its primary target of diabetic retinopathy, the study revealed an additional benefit: improvements in diabetic macular edema among treated patients. This dual action could potentially address multiple aspects of diabetic eye disease with a single therapeutic approach.
Expanding Clinical Development Program
OTX-TKI is currently under evaluation in two phase 3 trials, designated SOL-1 and SOL-R, for wet age-related macular degeneration. Building on the positive HELIOS trial results, Dr. Kaiser announced plans to initiate a dedicated phase 3 clinical study for diabetic retinopathy in 2024.
Novel Drug Delivery Approach
The implant format of OTX-TKI represents an innovative approach to ocular drug delivery. This delivery system could potentially offer advantages over traditional treatment methods, particularly in terms of treatment durability and patient compliance.
The advancement of OTX-TKI into phase 3 trials for diabetic retinopathy marks a significant step forward in addressing the needs of patients with this serious eye condition. The planned clinical trial will further evaluate the safety and efficacy of this promising therapeutic approach.
